{"organizations": [], "uuid": "e0fc022c51e58b3f192bc10e99bb70a26a1f72d6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/06/the-associated-press-gilead-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Gilead reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T23:45:00.000+02:00", "replies_count": 0, "uuid": "e0fc022c51e58b3f192bc10e99bb70a26a1f72d6"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/06/the-associated-press-gilead-reports-4q-loss.html", "ord_in_thread": 0, "title": "Gilead reports 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "foster city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "foster city", "sentiment": "none"}], "organizations": [{"name": "gilead", "sentiment": "negative"}, {"name": "gilead sciences inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "standard & poor", "sentiment": "none"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Tuesday reported a fourth-quarter loss of $3.87 billion, after reporting a profit in the same period a year earlier.\nThe Foster City, California-based company said it had a loss of $2.96 per share. Earnings, adjusted for one-time gains and costs, came to $1.78 per share.\nThe results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $1.70 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $5.95 billion in the period, which also topped Street forecasts. Eight analysts surveyed by Zacks expected $5.78 billion.\nGilead expects full-year earnings in the range of $1.41 to $1.51 per share.\nGilead shares have risen 12 percent since the beginning of the year, while the Standard & Poor's 500 index has climbed almost 1 percent. In the final minutes of trading on Tuesday, shares hit $80.38, a rise of 11 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on GILD at https://www.zacks.com/ap/GILD", "external_links": [], "published": "2018-02-06T23:45:00.000+02:00", "crawled": "2018-02-07T01:52:03.004+02:00", "highlightTitle": ""}